Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
about
Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapyPrediction of novel drug indications using network driven biological data prioritization and integration.Proposed mechanisms of action for prostate cancer vaccines.Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.The tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita.In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway.Tumor lysate-loaded biodegradable microparticles as cancer vaccines.Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.Personalized peptide vaccines and their relation to other therapies in urological cancer.PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.Inhibition of prostate cancer growth by immunization with a GM-CSF-modified mouse prostate cancer RM-1 cell vaccine in a novel murine model.Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells.Efficacy of granulocyte-macrophage colony-stimulating factor combined with metronomic paclitaxel in the treatment of Lewis lung carcinoma transplanted in mice.Vitamin E-rich Nanoemulsion Enhances the Antitumor Efficacy of Low-Dose Paclitaxel by Driving Th1 Immune Response.
P2860
Q27027093-43014EFC-44D9-45B4-8CCA-736BE2C6A784Q30727519-9E1BB539-4D60-4AC1-8F02-E3223FFE57D6Q35174754-437260EE-81B5-43AD-98C8-D2FD0F4B5E01Q35713347-3A41D784-8F87-4A7F-93B3-F6C8C3CEBB6DQ35870629-684478BA-E0AF-4E0C-9767-4B3250154676Q37474087-55951E86-8F16-4808-B7E9-C94AB53186A3Q37670779-06647F22-52FA-43A9-96CC-C5494B59AC02Q38002844-3EAC92AB-45EC-4053-9EF4-4FFBFBA12681Q39340541-5B3D9D6A-CB6B-4141-9871-48B9D8A5587DQ47291286-DC9F5095-9B44-4D7A-A758-E3ECFB04F635Q47547633-2FC2504E-D584-40DD-8E86-E23238E04751Q49747089-38B44B41-29C0-42C5-8B20-5D0414F488D6Q50045837-61EE3302-5E89-4100-97C9-43192A6EF32BQ53414165-AC66EA49-049C-4B15-9CFC-FA22DBBB40EE
P2860
Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Low-dose paclitaxel enhances t ...... ouse model of prostate cancer.
@en
Low-dose paclitaxel enhances t ...... ouse model of prostate cancer.
@nl
type
label
Low-dose paclitaxel enhances t ...... ouse model of prostate cancer.
@en
Low-dose paclitaxel enhances t ...... ouse model of prostate cancer.
@nl
prefLabel
Low-dose paclitaxel enhances t ...... ouse model of prostate cancer.
@en
Low-dose paclitaxel enhances t ...... ouse model of prostate cancer.
@nl
P2093
P2860
P1476
Low-dose paclitaxel enhances t ...... ouse model of prostate cancer.
@en
P2093
Jinlong Li
Qiushan He
Weihua Yin
Xiaoren Zhang
P2860
P2888
P304
P356
10.1007/S00262-011-0988-4
P577
2011-02-18T00:00:00Z